JDOC vs. GNOM

Last updated Apr 2, 2026

Compare and contrast key facts about Jpmorgan Healthcare Leaders ETF (JDOC) and Global X Genomics & Biotechnology ETF (GNOM).

JDOC and GNOM are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. JDOC is an actively managed fund by JPMorgan. It was launched on Nov 1, 2023. GNOM is a passively managed fund by Global X that tracks the performance of the Solactive Genomics Index. It was launched on Apr 5, 2019.

Performance

JDOC vs. GNOM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Jpmorgan Healthcare Leaders ETF (JDOC) and Global X Genomics & Biotechnology ETF (GNOM). The values are adjusted to include any dividend payments, if applicable.

JDOC vs. GNOM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
JDOC Jpmorgan Healthcare Leaders ETF	-3.14%	15.36%	-1.04%	10.71%
GNOM Global X Genomics & Biotechnology ETF	-2.79%	18.65%	-15.99%	25.22%

Returns By Period

In the year-to-date period, JDOC achieves a -3.14% return, which is significantly lower than GNOM's -2.79% return.

JDOC

• 1D: 0.85%
• 1M: -4.69%
• YTD: -3.14%
• 6M: 4.71%
• 1Y: 7.88%
• 3Y*: —
• 5Y*: —
• 10Y*: —

GNOM

• 1D: 1.02%
• 1M: -6.22%
• YTD: -2.79%
• 6M: 12.23%
• 1Y: 44.15%
• 3Y*: -3.13%
• 5Y*: -13.13%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

JDOC vs. GNOM - Expense Ratio Comparison

JDOC has a 0.65% expense ratio, which is higher than GNOM's 0.50% expense ratio.

JDOC

Jpmorgan Healthcare Leaders ETF

GNOM

Global X Genomics & Biotechnology ETF

Return for Risk

JDOC vs. GNOM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

JDOC

JDOC Risk / Return Rank: 23
JDOC Sharpe Ratio Rank: 25
JDOC Sortino Ratio Rank: 24
JDOC Omega Ratio Rank: 23
JDOC Calmar Ratio Rank: 24
JDOC Martin Ratio Rank: 21

GNOM

GNOM Risk / Return Rank: 73
GNOM Sharpe Ratio Rank: 75
GNOM Sortino Ratio Rank: 77
GNOM Omega Ratio Rank: 68
GNOM Calmar Ratio Rank: 78
GNOM Martin Ratio Rank: 69

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

JDOC vs. GNOM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Jpmorgan Healthcare Leaders ETF (JDOC) and Global X Genomics & Biotechnology ETF (GNOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	JDOC	GNOM	Difference
Sharpe ratio Return per unit of total volatility	0.47	1.43	-0.96
Sortino ratio Return per unit of downside risk	0.75	2.04	-1.29
Omega ratio Gain probability vs. loss probability	1.10	1.26	-0.16
Calmar ratio Return relative to maximum drawdown	0.62	2.25	-1.63
Martin ratio Return relative to average drawdown	1.53	7.43	-5.90
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

JDOC vs. GNOM - Sharpe Ratio Comparison

The current JDOC Sharpe Ratio is 0.47, which is lower than the GNOM Sharpe Ratio of 1.43. The chart below compares the historical Sharpe Ratios of JDOC and GNOM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	JDOC	GNOM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.47	1.43	-0.96
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.39	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.62	-0.13	+0.75

Correlation

The correlation between JDOC and GNOM is 0.64, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

JDOC vs. GNOM - Dividend Comparison

JDOC's dividend yield for the trailing twelve months is around 0.91%, less than GNOM's 1.41% yield.

	TTM	2025	2024	2023	2022	2021	2020
JDOC Jpmorgan Healthcare Leaders ETF	0.91%	0.89%	5.57%	0.15%	0.00%	0.00%	0.00%
GNOM Global X Genomics & Biotechnology ETF	1.41%	1.37%	0.00%	0.00%	0.00%	0.03%	0.14%

Drawdowns

JDOC vs. GNOM - Drawdown Comparison

The maximum JDOC drawdown since its inception was -20.87%, smaller than the maximum GNOM drawdown of -75.00%. Use the drawdown chart below to compare losses from any high point for JDOC and GNOM.

Drawdown Indicators

	JDOC	GNOM	Difference
Max Drawdown Largest peak-to-trough decline	-20.87%	-75.00%	+54.13%
Max Drawdown (1Y) Largest decline over 1 year	-9.68%	-18.17%	+8.49%
Max Drawdown (5Y) Largest decline over 5 years	—	-72.29%	—
Current Drawdown Current decline from peak	-6.17%	-59.83%	+53.66%
Average Drawdown Average peak-to-trough decline	-7.01%	-40.12%	+33.11%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.95%	5.51%	-1.56%

Volatility

JDOC vs. GNOM - Volatility Comparison

The current volatility for Jpmorgan Healthcare Leaders ETF (JDOC) is 5.65%, while Global X Genomics & Biotechnology ETF (GNOM) has a volatility of 10.76%. This indicates that JDOC experiences smaller price fluctuations and is considered to be less risky than GNOM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	JDOC	GNOM	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.65%	10.76%	-5.11%
Volatility (6M) Calculated over the trailing 6-month period	9.95%	19.71%	-9.76%
Volatility (1Y) Calculated over the trailing 1-year period	17.05%	31.21%	-14.16%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	14.32%	33.65%	-19.33%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	14.32%	34.30%	-19.98%